肝癌TACE治疗后存活5年以上病例相关因素对比分析
|
摘要
第一部分肝癌TACE后存活5年以上病例DSA和CT分析
目的:回顾性分析肝癌TACE治疗后存活五年以上和一年以内病例的DSA和CT表现。重点分析DSA造影片和CT片中肿瘤病灶的大小、数目、病灶染色表现、血供丰富与否、参与血供的靶血管情况、动静脉瘘情况、静脉内癌栓情况、碘化油在肿瘤内的沉积情况,总结他们各自的cT和DSA表现特点,以期为临床判断预后提供有价值的信息。
材料和方法:收集首次TACE治疗后存活五年以上肝癌病人104人作为观察组,首次TACE治疗时年龄24-80岁,平均56岁。男性93人,女性11人。其中69例病人由手术(65例)或穿刺(4例)得到病理诊断。65例为肝细胞肝癌,2例为混合细胞性,2例为胆管细胞癌,其余病例为临床诊断。另收集同期进行TACE治疗,生存一年以内肝癌病例52例,作为对照组。首次TACE治疗时年龄17-72岁,平均51岁。男性45人,女性7人。其中14例病人有手术病理或穿刺病理证实为肝细胞肝癌,其余病例为临床诊断。两组病人的介入治疗方法均为以TACE为主的综合治疗。其中TACE时选用碘化油和明胶海绵作为栓塞剂。碘化油用量依病灶大小、肝功能情况及DSA显示有无动静脉瘘及有无静脉内癌栓决定。分析两组病例DSA造影片及CT片。重点分析肿瘤病灶的大小、数目、病灶染色表现、血供丰富与否、参与血供的靶血管情况、动静脉瘘情况、静脉内癌栓情况、碘化油在肿瘤内的沉积情况。
结果:观察组中,最短生存期5年,最长15年以上,至今存活。59例病人为手术后复发病人,14例病人接受过二次手术,6例病人TACE治疗过程中接受过Ⅱ期手术或肝移植治疗。TACE治疗次数最多18次,最少4次。两次TACE手术间隔最短6周,最长4年。末次TACE至存活最长8年。首次TACE治疗时单个病灶直径最大15cm,最小1cm。多个病灶最多7个,累加直径16cm。各肝叶均有分布。病灶均为富血供,未见明显的动静脉瘘。门静脉主干及肝静脉2级分支内均无癌栓。首次TACE时病灶单支血供83例,多支(2支或以上)21例。末次TACE时单支血供57例,多支血供47例。所有病例均有过CT显示碘油病灶内沉积良好时期。6.7%(7/104)病例有肿瘤所在肝段萎缩表现,7.7%(8/104)病例有胆汁瘤样改变出现;对照组中,最短生存划4月,最长12月,13例病人为手术后复发病人,无Ⅱ期手术切除病例。T A C E治疗次数最多6次,最少1次。两次T A C E手术间隔最短1月,最长3月。首次T A C E治疗时单个病灶直径最大25cm,最小12cm;病灶多发者中最多者呈弥漫分布难以计数,累加病灶占据肝脏体积的70%左右。病灶各叶均有分布,均为富血供,59.6%(31/52)病例有明显的动静脉瘘。48.1%(25/25)病例门静脉内有癌栓。15.4%(8/52)病例肝静脉内有癌栓。首次T AC E时病灶单支血供39例,多支血供13例。末次T A C E时单支血供35例,多支血供17例。14例病例有过DSA下显示碘油沉积较好,仅3例有过CT显示病灶内碘油沉积良好阶段。无一病例有肿瘤所在肝段萎缩和胆汁瘤样改变出现。
结论:T A C E治疗后存活5年以上病例的DSA和CT与存活1年以内病例相对比,其特点为:长期生存者的病灶相对较小(单个病灶直径最大15cm,多个病灶累加直径最大16cm)。没有明显的动静脉瘘和静脉内癌栓,CT显示病灶内碘油沉积良好,部分病例有肿瘤所在肝段萎缩或出现胆汁瘤样改变。肝脏肿瘤供血动脉随TA C E治疗次数增多而逐渐纤细,如有病灶存活,往往有侧支供血出现。
第二部分肝癌TACE治疗后存活5年以上病例临床相关因素观察
目的:回顾性分析肝癌TACE治疗后存活五年以上病例的临床相关因素,并和同期生存时间不满一年的肝癌患者进行对照,探讨影响TACE长期疗效的因素,以期客观评估TACE治疗和其他治疗方法的联合应用价值。
材料和方法:收集首次TACE治疗后存活五年以上肝癌病人62例作为观察组。男性53人,女性9人。首次TACE治疗时年龄24-80岁,平均58岁。其中39例得到病理诊断,23例为临床诊断。观察组病例中,首次TACE治疗前均有不同程度的肝硬化,肝功能按Child-Pugh分级,A级45例,B级17例。治疗前均无血行和淋巴系统远处转移。38例病人首次治疗前AFP＞400ng/ml.24例病人首次治疗前AFP＜400ng/ml.另收集同期进行TACE治疗,生存一年以内肝癌病例52例作为对照组。首次TACE治疗时年龄17-72岁,平均51岁。男性45人,女性7人。其中14例病人得到病理珍断为肝细胞肝癌,其余病例为临床诊断。34例病人首次治疗前AFP＞400ng/ml.18例病人首次治疗前AFP＜400ng/ml.52例对照组组病例中,首次TACE治疗前均有不同程度的肝硬化,肝功能按Child-Pugh分级,A级25例,B级27例。治疗前均无血行和淋巴系统远处转移。肝癌分期:观察组属Ⅰ期24例,Ⅱa期26例,Ⅱb期12例(Ⅱa期前占80.6%,50/62);对照组属Ⅱb期27例,Ⅲ期25例(Ⅱb后病例为100%,52/52)。两组病人的介入治疗方法均为以TACE为主的综合治疗。分析两者病例各自的TACE术前的基础肝功能情况,肿瘤的临床分期、TACE术中的肝功能保护、TACE的次数和间隔、碘化油用量和方法、动静脉瘘和门静脉癌栓的处理、肝内转移和远处转移灶出现的情况、伴发病变的介入处理、TACE和其他治疗方法的联合应用。
结果:观察组中,生存期5年者26例,6年以上者36例。对照组中,最短生存期4月,最长12月。两组病人的临床分期有差异(P＜0.05),观察组的病人Ⅰ期及Ⅱa期居多;对照组的病例以Ⅱb期及Ⅲ期为主。观察组中首次TACE治疗前AFP阳性者38例,治疗后有34例AFP下降至正常;对照组AFP阳性者34例,治疗后,仅有8例转阴。观察组中TACE治疗次数最多18次,最少4次。两次TACE手术间隔最短6周,最长4年。对照组中TACE治疗次数最多6次,最少1次。两次TACE手术间隔最短1月,最长3月。观察组中首次TACE治疗时单个病灶直径最大15cm;多个病灶最多7个,累加直径16cm。各肝叶均有分布。未见明显的动静脉瘘,门静脉主干及肝静脉2级分支内均无癌栓。对照组中首次TACE治疗时单个病灶直径最大25cm,最小12cm;病灶多发者中最多者呈弥漫分布难以计数,累加占居肝脏体积的70%左右。各肝叶均有分布。59.6%病例有动静脉瘘,48.1%病例门静脉内有癌栓。观察组中有40.3%病人采用单纯TACE治疗模式,55.8%病人采用TACE联合其他治疗。对照组中有78.8%病人采用单纯TACE治疗模式,21.2%病人采用TACE联合其他治疗。两组采取综合治疗的病人比例差异无统计学意义(P＞0.05)。观察组有45.2%病人有肝内新病灶产生,33.9%病人有远处转移。对照组中有92.3%病人有肝内病灶未得到控制而继续增大。19.2%有远处转移。两组病人的远处转移的发生率有统计学意义(P＜0.05)。
结论:TACE治疗后存活5年以上病例的临床相关因素与存活1年以内病例相对比,其临床特点为:长期生存者的肝癌的病灶相对较小,临床分期为Ⅱa期以前的占80.6%,没有Ⅲ期的病人;肝功能较好,分级为Child-Pugh A或B级;AFP经TACE治疗后转阴率高。没有明显的动静脉瘘和静脉内癌栓。治疗上的特点为TACE时除对肿瘤作化疗栓塞外,尽可能保护肝功能。TACE后采取综合治疗,保护肝功能,尽可能延长2次TACE手术的间隔时间。
Part I Observation of the image of CT and DSA in the patients with HCC who were survived more then 5 years after treated by TACE
Objective: To observe the CT findings and the image of DSA in the patients with PLC who were survived more than 5 years after treated by TACE .
Materials and Methods : 104 patients of PLC (primary liver cancer) who were survived more than 5 years after treated by TACE were collected as a trial group. The age were 24-80 years old when the first TACE was done, average is 56 years old. Male was 93 and female was 11. There were 65 cases diagnosed as hepatocellular carcinoma, 2 cases diagnosed as cholangiocarcinoma, 2 cases diagnosed as cholangiohepatocellular carcinoma by the pathology. Others diagnosed as hepatocellular carcinoma by the clinical diagnosis. Another 52 cases of PLC who were survived less than 1 year after treated by TACE were collected as a contrast group. The age were 17-72 years old when the first TACE was done, average is 51 years old. Male was 45 and female was 7. There were 14 cases diagnosed as hepatocellular carcinoma by the pathology. Others diagnosed as hepatocellular carcinoma by the clinical diagnosis. The main therapy was TACE plus PEI, RFA, radiotherapy and so on in the two groups. The CT findings and the image of DSA were be analysed.
Results: In the trial group, the longest survived time were more than 15 years and the patient still lived well so far. 59 cases were recurrent hepatocellular carcinoma after surgery. 14 cases were get second surgery, 6 cases got second phase surgery in the period of interventional radiology. The number of the TACE is 4-18 times. The period time of the two TACE is between 6 weeks to 4 years. The longest one from the latest TACE to survived time is 8 years. The largest diameter of the single tumor is 15 cm. The cumulated total diameter of the multiple tumors is 16 cm. All tumors were abundant with blood supply. There was no obvious A-V short in the tumor. The blood supply of the tumor is single branch in 83 cases, multiple branches in 21 cases when the first TACE was done. But in the end of the TACE the blood supply of the tumor is single branch in 57 cases, multiple ones in 47 cases. All the cases had the period that the tumor was full filled with lipiodol. 7 cases showed there was atrophy in the section of the liver where the tumor located. 8 cases biloma occurs. In the contrast group, the longest survived time was 1 year. 13 cases were recurrent hepatocellular carcinoma after surgery. No case got second phase surgery. The number of the TACE is 1-6 times. The period time of the two TACE was between 1 to 3 months. The largest diameter of the single tumor is 25 cm. There was obvious A-V short in the 31 cases, portal vein embolism in the 25 cases. The blood supply of the tumor is single branch in 39 cases, multiple ones in 13 cases when the first TACE was done. But in the end of the TACE the blood supply of the tumor is single branch in 35 cases, the multiple one in 17cases. Only 3 cases had the period that the tumor was full filled with lipiodol on the CT scan view. There were no cases showed atrophy in the section of the liver and no biloma occurs.
Conclusion: The characteristic of the CT findings and the DSA images in the patients with PLC who were survived more than 5 years after treated by TACE are: smaller tumor, no A-V short, no embolism in the vein, full filled of lipiodol in the tumor. Some cases got atrophy in the section of the liver where the tumor located. Some cases biloma occurs.
Part II Observation study of clinical correlative factor in the patients with HCC who were survived more then 5 years after treated by TACE
Objective: To observe the clinical correlative factor in the patients ill with HCC who were survived more then 5 years after treated by TACE.
Materials and Methods : 62 patients of PLC (primary liver cancer) who were survived more than 5 years after treated by TACE were collected as a trial group. The age were 24-80 years old when the first TACE was done, average is 58 years old. Male was 53 and female was 9. There were 39 cases diagnosed by the pathology. Others diagnosed by the clinical. There were varies cirrohis in all cases before first TACE. The liver function was Class A Child-pugh in 45 cases. Class B in 17 cases. No class C patient in this group. There was no metastasis tumor in the other part of the body before the first time of the TACE. Another 52 cases of PLC who were survived less than 1 year after treated by TACE were collected as a contrast group. The age were 17-72 years old when the first TACE was done, average is 51 years old. Male was 45 and female was 7. There were 14 cases diagnosed as hepatocellular carcinoma by the pathology. Others diagnosed as hepatocellular carcinoma by the clinical diagnosis. There were varies cirrohis in all cases before first TACE. The liver function was Child-pugh class A in the 25 cases, Child-pugh class B in the 27 cases. No class C patients, too. There was no metastasis tumor in the other part of the body before the first time of the TACE. 24 cases belong to I stage, 26 cases belong to IIa stage and 12 cases belong to IIb stage in the trial group. 27 cases belong to IIb stage, 25cases belong to III stage in the contrast group. The main therapy was TACE plus PEI, RFA, radiotherapy and so on in the two groups. The liver function, clinical stage of the tumor, the time number and the separate time of the TACE, the dose of the lopiodol and so on were analysed.
Results: In the trial group, 26 cases got survived more than 5 years and 36 patients got survived more than 6 years. In the contrast group, the longest survived time was 1 year. There was obvious difference between 2 groups in the clinical stage (P<0.05). Almost 80% cases were II stage in the trail group. Almost 70% cases were III stage in the contrast group. AFP positive cases turns to negative about 34/38 in the trail group, only 8/34 cases turns to negative in contrast group. In the trail group, the number of the TACE is 4-18 times. The period time of the two TACE is between 6 weeks to 4 years. The longest one from the latest TACE to survived time is 8 years. The largest diameter of the single tumor is 15 cm. The cumulated total diameter of the multiple tumors is 16 cm. All tumors were abundant with blood supply. There was no obvious A-V short in the tumor. While in the contrast group, the number of the TACE is 1-6 times. The period time of the two TACE was between 1 to 3 months. The largest diameter of the single tumor is 25 cm. There was obvious A-V short in the 31 cases, portal vein embolism in the 25 cases. In the trail group, there was 45.2% cases got recover hepatocellular carcinoma in the hepatic lobe and 33.9% cases got metastasis tumor in the other organ of the body. Metastasis tumor almost occurs on the 3 years later after first TACE. While in the contrast group, 10 cases (19.2%, 10/52) got metastasis tumor in the lung.
Conclusion: The characteristic of the clinical correlative factor in the patients with PLC who were survived more than 5 years after treated by TACE are: smaller tumor,early clinical stage of the tumour, liver function in Class A or Class B, AFP positive canturns to negative and kept a long period of the time. The protection of the liverfunction was very important while the TACE procedure were be done.
目的:回顾性分析肝癌TACE治疗后存活五年以上和一年以内病例的DSA和CT表现。重点分析DSA造影片和CT片中肿瘤病灶的大小、数目、病灶染色表现、血供丰富与否、参与血供的靶血管情况、动静脉瘘情况、静脉内癌栓情况、碘化油在肿瘤内的沉积情况,总结他们各自的cT和DSA表现特点,以期为临床判断预后提供有价值的信息。
材料和方法:收集首次TACE治疗后存活五年以上肝癌病人104人作为观察组,首次TACE治疗时年龄24-80岁,平均56岁。男性93人,女性11人。其中69例病人由手术(65例)或穿刺(4例)得到病理诊断。65例为肝细胞肝癌,2例为混合细胞性,2例为胆管细胞癌,其余病例为临床诊断。另收集同期进行TACE治疗,生存一年以内肝癌病例52例,作为对照组。首次TACE治疗时年龄17-72岁,平均51岁。男性45人,女性7人。其中14例病人有手术病理或穿刺病理证实为肝细胞肝癌,其余病例为临床诊断。两组病人的介入治疗方法均为以TACE为主的综合治疗。其中TACE时选用碘化油和明胶海绵作为栓塞剂。碘化油用量依病灶大小、肝功能情况及DSA显示有无动静脉瘘及有无静脉内癌栓决定。分析两组病例DSA造影片及CT片。重点分析肿瘤病灶的大小、数目、病灶染色表现、血供丰富与否、参与血供的靶血管情况、动静脉瘘情况、静脉内癌栓情况、碘化油在肿瘤内的沉积情况。
结果:观察组中,最短生存期5年,最长15年以上,至今存活。59例病人为手术后复发病人,14例病人接受过二次手术,6例病人TACE治疗过程中接受过Ⅱ期手术或肝移植治疗。TACE治疗次数最多18次,最少4次。两次TACE手术间隔最短6周,最长4年。末次TACE至存活最长8年。首次TACE治疗时单个病灶直径最大15cm,最小1cm。多个病灶最多7个,累加直径16cm。各肝叶均有分布。病灶均为富血供,未见明显的动静脉瘘。门静脉主干及肝静脉2级分支内均无癌栓。首次TACE时病灶单支血供83例,多支(2支或以上)21例。末次TACE时单支血供57例,多支血供47例。所有病例均有过CT显示碘油病灶内沉积良好时期。6.7%(7/104)病例有肿瘤所在肝段萎缩表现,7.7%(8/104)病例有胆汁瘤样改变出现;对照组中,最短生存划4月,最长12月,13例病人为手术后复发病人,无Ⅱ期手术切除病例。T A C E治疗次数最多6次,最少1次。两次T A C E手术间隔最短1月,最长3月。首次T A C E治疗时单个病灶直径最大25cm,最小12cm;病灶多发者中最多者呈弥漫分布难以计数,累加病灶占据肝脏体积的70%左右。病灶各叶均有分布,均为富血供,59.6%(31/52)病例有明显的动静脉瘘。48.1%(25/25)病例门静脉内有癌栓。15.4%(8/52)病例肝静脉内有癌栓。首次T AC E时病灶单支血供39例,多支血供13例。末次T A C E时单支血供35例,多支血供17例。14例病例有过DSA下显示碘油沉积较好,仅3例有过CT显示病灶内碘油沉积良好阶段。无一病例有肿瘤所在肝段萎缩和胆汁瘤样改变出现。
结论:T A C E治疗后存活5年以上病例的DSA和CT与存活1年以内病例相对比,其特点为:长期生存者的病灶相对较小(单个病灶直径最大15cm,多个病灶累加直径最大16cm)。没有明显的动静脉瘘和静脉内癌栓,CT显示病灶内碘油沉积良好,部分病例有肿瘤所在肝段萎缩或出现胆汁瘤样改变。肝脏肿瘤供血动脉随TA C E治疗次数增多而逐渐纤细,如有病灶存活,往往有侧支供血出现。
第二部分肝癌TACE治疗后存活5年以上病例临床相关因素观察
目的:回顾性分析肝癌TACE治疗后存活五年以上病例的临床相关因素,并和同期生存时间不满一年的肝癌患者进行对照,探讨影响TACE长期疗效的因素,以期客观评估TACE治疗和其他治疗方法的联合应用价值。
材料和方法:收集首次TACE治疗后存活五年以上肝癌病人62例作为观察组。男性53人,女性9人。首次TACE治疗时年龄24-80岁,平均58岁。其中39例得到病理诊断,23例为临床诊断。观察组病例中,首次TACE治疗前均有不同程度的肝硬化,肝功能按Child-Pugh分级,A级45例,B级17例。治疗前均无血行和淋巴系统远处转移。38例病人首次治疗前AFP＞400ng/ml.24例病人首次治疗前AFP＜400ng/ml.另收集同期进行TACE治疗,生存一年以内肝癌病例52例作为对照组。首次TACE治疗时年龄17-72岁,平均51岁。男性45人,女性7人。其中14例病人得到病理珍断为肝细胞肝癌,其余病例为临床诊断。34例病人首次治疗前AFP＞400ng/ml.18例病人首次治疗前AFP＜400ng/ml.52例对照组组病例中,首次TACE治疗前均有不同程度的肝硬化,肝功能按Child-Pugh分级,A级25例,B级27例。治疗前均无血行和淋巴系统远处转移。肝癌分期:观察组属Ⅰ期24例,Ⅱa期26例,Ⅱb期12例(Ⅱa期前占80.6%,50/62);对照组属Ⅱb期27例,Ⅲ期25例(Ⅱb后病例为100%,52/52)。两组病人的介入治疗方法均为以TACE为主的综合治疗。分析两者病例各自的TACE术前的基础肝功能情况,肿瘤的临床分期、TACE术中的肝功能保护、TACE的次数和间隔、碘化油用量和方法、动静脉瘘和门静脉癌栓的处理、肝内转移和远处转移灶出现的情况、伴发病变的介入处理、TACE和其他治疗方法的联合应用。
结果:观察组中,生存期5年者26例,6年以上者36例。对照组中,最短生存期4月,最长12月。两组病人的临床分期有差异(P＜0.05),观察组的病人Ⅰ期及Ⅱa期居多;对照组的病例以Ⅱb期及Ⅲ期为主。观察组中首次TACE治疗前AFP阳性者38例,治疗后有34例AFP下降至正常;对照组AFP阳性者34例,治疗后,仅有8例转阴。观察组中TACE治疗次数最多18次,最少4次。两次TACE手术间隔最短6周,最长4年。对照组中TACE治疗次数最多6次,最少1次。两次TACE手术间隔最短1月,最长3月。观察组中首次TACE治疗时单个病灶直径最大15cm;多个病灶最多7个,累加直径16cm。各肝叶均有分布。未见明显的动静脉瘘,门静脉主干及肝静脉2级分支内均无癌栓。对照组中首次TACE治疗时单个病灶直径最大25cm,最小12cm;病灶多发者中最多者呈弥漫分布难以计数,累加占居肝脏体积的70%左右。各肝叶均有分布。59.6%病例有动静脉瘘,48.1%病例门静脉内有癌栓。观察组中有40.3%病人采用单纯TACE治疗模式,55.8%病人采用TACE联合其他治疗。对照组中有78.8%病人采用单纯TACE治疗模式,21.2%病人采用TACE联合其他治疗。两组采取综合治疗的病人比例差异无统计学意义(P＞0.05)。观察组有45.2%病人有肝内新病灶产生,33.9%病人有远处转移。对照组中有92.3%病人有肝内病灶未得到控制而继续增大。19.2%有远处转移。两组病人的远处转移的发生率有统计学意义(P＜0.05)。
结论:TACE治疗后存活5年以上病例的临床相关因素与存活1年以内病例相对比,其临床特点为:长期生存者的肝癌的病灶相对较小,临床分期为Ⅱa期以前的占80.6%,没有Ⅲ期的病人;肝功能较好,分级为Child-Pugh A或B级;AFP经TACE治疗后转阴率高。没有明显的动静脉瘘和静脉内癌栓。治疗上的特点为TACE时除对肿瘤作化疗栓塞外,尽可能保护肝功能。TACE后采取综合治疗,保护肝功能,尽可能延长2次TACE手术的间隔时间。
Part I Observation of the image of CT and DSA in the patients with HCC who were survived more then 5 years after treated by TACE
Objective: To observe the CT findings and the image of DSA in the patients with PLC who were survived more than 5 years after treated by TACE .
Materials and Methods : 104 patients of PLC (primary liver cancer) who were survived more than 5 years after treated by TACE were collected as a trial group. The age were 24-80 years old when the first TACE was done, average is 56 years old. Male was 93 and female was 11. There were 65 cases diagnosed as hepatocellular carcinoma, 2 cases diagnosed as cholangiocarcinoma, 2 cases diagnosed as cholangiohepatocellular carcinoma by the pathology. Others diagnosed as hepatocellular carcinoma by the clinical diagnosis. Another 52 cases of PLC who were survived less than 1 year after treated by TACE were collected as a contrast group. The age were 17-72 years old when the first TACE was done, average is 51 years old. Male was 45 and female was 7. There were 14 cases diagnosed as hepatocellular carcinoma by the pathology. Others diagnosed as hepatocellular carcinoma by the clinical diagnosis. The main therapy was TACE plus PEI, RFA, radiotherapy and so on in the two groups. The CT findings and the image of DSA were be analysed.
Results: In the trial group, the longest survived time were more than 15 years and the patient still lived well so far. 59 cases were recurrent hepatocellular carcinoma after surgery. 14 cases were get second surgery, 6 cases got second phase surgery in the period of interventional radiology. The number of the TACE is 4-18 times. The period time of the two TACE is between 6 weeks to 4 years. The longest one from the latest TACE to survived time is 8 years. The largest diameter of the single tumor is 15 cm. The cumulated total diameter of the multiple tumors is 16 cm. All tumors were abundant with blood supply. There was no obvious A-V short in the tumor. The blood supply of the tumor is single branch in 83 cases, multiple branches in 21 cases when the first TACE was done. But in the end of the TACE the blood supply of the tumor is single branch in 57 cases, multiple ones in 47 cases. All the cases had the period that the tumor was full filled with lipiodol. 7 cases showed there was atrophy in the section of the liver where the tumor located. 8 cases biloma occurs. In the contrast group, the longest survived time was 1 year. 13 cases were recurrent hepatocellular carcinoma after surgery. No case got second phase surgery. The number of the TACE is 1-6 times. The period time of the two TACE was between 1 to 3 months. The largest diameter of the single tumor is 25 cm. There was obvious A-V short in the 31 cases, portal vein embolism in the 25 cases. The blood supply of the tumor is single branch in 39 cases, multiple ones in 13 cases when the first TACE was done. But in the end of the TACE the blood supply of the tumor is single branch in 35 cases, the multiple one in 17cases. Only 3 cases had the period that the tumor was full filled with lipiodol on the CT scan view. There were no cases showed atrophy in the section of the liver and no biloma occurs.
Conclusion: The characteristic of the CT findings and the DSA images in the patients with PLC who were survived more than 5 years after treated by TACE are: smaller tumor, no A-V short, no embolism in the vein, full filled of lipiodol in the tumor. Some cases got atrophy in the section of the liver where the tumor located. Some cases biloma occurs.
Part II Observation study of clinical correlative factor in the patients with HCC who were survived more then 5 years after treated by TACE
Objective: To observe the clinical correlative factor in the patients ill with HCC who were survived more then 5 years after treated by TACE.
Materials and Methods : 62 patients of PLC (primary liver cancer) who were survived more than 5 years after treated by TACE were collected as a trial group. The age were 24-80 years old when the first TACE was done, average is 58 years old. Male was 53 and female was 9. There were 39 cases diagnosed by the pathology. Others diagnosed by the clinical. There were varies cirrohis in all cases before first TACE. The liver function was Class A Child-pugh in 45 cases. Class B in 17 cases. No class C patient in this group. There was no metastasis tumor in the other part of the body before the first time of the TACE. Another 52 cases of PLC who were survived less than 1 year after treated by TACE were collected as a contrast group. The age were 17-72 years old when the first TACE was done, average is 51 years old. Male was 45 and female was 7. There were 14 cases diagnosed as hepatocellular carcinoma by the pathology. Others diagnosed as hepatocellular carcinoma by the clinical diagnosis. There were varies cirrohis in all cases before first TACE. The liver function was Child-pugh class A in the 25 cases, Child-pugh class B in the 27 cases. No class C patients, too. There was no metastasis tumor in the other part of the body before the first time of the TACE. 24 cases belong to I stage, 26 cases belong to IIa stage and 12 cases belong to IIb stage in the trial group. 27 cases belong to IIb stage, 25cases belong to III stage in the contrast group. The main therapy was TACE plus PEI, RFA, radiotherapy and so on in the two groups. The liver function, clinical stage of the tumor, the time number and the separate time of the TACE, the dose of the lopiodol and so on were analysed.
Results: In the trial group, 26 cases got survived more than 5 years and 36 patients got survived more than 6 years. In the contrast group, the longest survived time was 1 year. There was obvious difference between 2 groups in the clinical stage (P<0.05). Almost 80% cases were II stage in the trail group. Almost 70% cases were III stage in the contrast group. AFP positive cases turns to negative about 34/38 in the trail group, only 8/34 cases turns to negative in contrast group. In the trail group, the number of the TACE is 4-18 times. The period time of the two TACE is between 6 weeks to 4 years. The longest one from the latest TACE to survived time is 8 years. The largest diameter of the single tumor is 15 cm. The cumulated total diameter of the multiple tumors is 16 cm. All tumors were abundant with blood supply. There was no obvious A-V short in the tumor. While in the contrast group, the number of the TACE is 1-6 times. The period time of the two TACE was between 1 to 3 months. The largest diameter of the single tumor is 25 cm. There was obvious A-V short in the 31 cases, portal vein embolism in the 25 cases. In the trail group, there was 45.2% cases got recover hepatocellular carcinoma in the hepatic lobe and 33.9% cases got metastasis tumor in the other organ of the body. Metastasis tumor almost occurs on the 3 years later after first TACE. While in the contrast group, 10 cases (19.2%, 10/52) got metastasis tumor in the lung.
Conclusion: The characteristic of the clinical correlative factor in the patients with PLC who were survived more than 5 years after treated by TACE are: smaller tumor,early clinical stage of the tumour, liver function in Class A or Class B, AFP positive canturns to negative and kept a long period of the time. The protection of the liverfunction was very important while the TACE procedure were be done.
引文
1.Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].CA:A Cancer Journal for Clinicians,2005,55(2):74-108.
2.Momosaki S,Nakashima Y,Kojiro M,et al.HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma.Journal of Viral Hepatitis,2005,12(3):325-329.
3.葛祖恂,黄介飞,陆守曾,等.国内丙型肝炎病毒感染与肝细胞癌关系的19个病例对照研究的Meta分析[J].中国卫生统计,1997,14(1):10-12.
4.Llovet JM,Burroughs A,Bruix J.Hepatocellular carcinoma[J].The Lancet,2003,362(9399):1907-1917.
5.曾运红,谭卫仙.原发性肝癌发病主要危险因素的Meta分析[J].现代预防医学,2004,3l(2):172-174.
6.曹海霞,丁建华,吴建中,等.饮酒习惯、HBsAg与原发性肝癌关系[J].中国肿瘤,2004,13(5):280-282.
7.Solbiati L,Coldberg SN,Lerace T,et al.Hepatic Metastases:Percutarleous radiofrequency ablation with cooledtip electrodes[J].Radiology,1997,205(2):367-373.
8.褚光平,蔡敬铭,刘强,等.青年人原发性肝癌的治疗与预后分析[J].中国肿瘤临床,2005,32(22):1299-1301.
9.Sturm JW,Keese MA,Bonninghoff RG,et al.Locally ablative therapies of hepatocellular carcinoma[J].Onkologie,2001,24(Suppl 5):35-45.
10.王建华.呼唤规范化的肝癌介入治疗[J].介入放射学杂志,2007,16(3):145-147.
11.Higuchi T,Kikuchi M,Okuzaki.Hepatocellular Carcinoma after Transcatheter Hepatic Arterial Embolization:a Histopathologic Study of 84 Resected Cases[J].Cancer,1994,73(31):2259-2261.
12.吴孟超.原发性肝癌的诊断及治疗进展[J].华夏医药,2006,4(1):10-11.
13.Livraghi T,Goldberg SN,Lazzaroni S,et al.Hepatocellular Carcinoma:Radiofrequcncy Ablation of Medium and Large Lesion[J].Radiology,2000,214(7):761-768.
14.Dong BW,Liang P,Yu XL,et al.Percutaneous Sonographically Guided Microwave Cagulation Therapy for Hepatocel]ular Carcinoma:Result in 234 Patients[J].Amercian Journal of Roentgenology,2003, 180(15):1547-1555.
15.Koda M,Murawaki Y,Mitsuda A,et al.Combination therapy withtranscatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alonefor patients with small hepatocellular carcinoma:a randomized control study[J].Cancer,2001,92(6):1516-1524.
16.王建华,周康荣.肝癌综合性介入治疗规范化方案(草案)[J].临床放射学杂志,2002,21:497-500.
1.中国抗癌协会肝癌专业委员会.原发性肝癌诊断标准[J].中华肝脏病杂志,2000,8(3):135.
2.王建华.肝癌综合介入治疗的现状[J].中华肝脏病杂志,2005,13(10):721-723.
3.陆才德.肝脏肿瘤的血供[J].国外医学:肿瘤学分册,1991,1(1):19-21.
4.Ackeman NB.Experimental Studies on the Role of the Portal Circulation in Hepatic Tumor Vascularity[J].Cancer,1986,58(8):1653-1657.
5.Doppman JL,Girton M,Kahn ER.Proximal versus peripheral hepatic artery embolization experimental study in monkeys[J].Radiology,1978,128(1):577-588.
6.罗建钧,颜志平,王建华,等.微球+碘化油联合栓塞与碘化油单独栓塞治疗肝癌的比较研究[J].中国医学计算机成像杂志,2008,14(2):154-159.
7.Matsuo N,Uchida H,Sakaguchi H,et al.Optimal lipiodol volume in transcatheter arterial chemoembolotherapy for hepatocellular carcinoma:study based on lipiodol accumulation patterns and histopathologic findings[J].Seminars in Oncology,1997,24(2 Suppl 6):61-70.
8.陈晓明,罗鹏飞,邵培坚,等.肝癌节段性栓塞化疗与常规栓塞化疗的比较研究[J].中华放射学杂志,2000,34(4):271-273.
9.曾庆乐,李彦豪,陈勇,等.微导管超选择插管在肝癌介入治疗中的应用[J].中国医学影像技术,2002,18(2):113-115
10.周泽健,罗鹏飞,邵培坚,等.介入治疗后38例中晚期肝癌患者生存5年以上的因素分析[J].中华放射学杂志,2002,36(9):792-796.
11.高伟明,孙东立,袁明远.碘化油用量与原发性肝癌介入治疗疗效关系研究[J].现代诊断与治疗,2006,17(6):346-347.
12.王建华.肝癌的介入治疗[J].实用医学杂志,200l,17(4):278-280.
13.刘嵘,王建华,颜志平,等.原发性肝癌综合介入治疗后存活5年以上56例患者临床分析[J].介入放射学杂志,2007,16(3):155-158.
14.肖承江,郑丽吟,蒋晓红.肝动脉栓塞化疗对肝损害的观察(附100例分析)[J].中华放射学杂志,1997,31(11):777-779.
15.姚问我,颜志平,王建华,等.介入治疗肝癌伴门脉癌栓的若干问题[J].中国临床医学,2007,14(6):810-811.
16.朱林忠,杨仁杰.原发性肝癌合并动静脉瘘的数字减影血管造影表现及介入治疗[J].北京大学学报(医学版),2008,40(2):129-134.
17.谭文华.原发性肝癌合并肝动静脉瘘的栓塞治疗(附10例报告)[J].广西医科大学学报,2003,20(4):600.
18.罗鹏飞,陈晓明,张良明,等.肝癌合并动静脉瘘的处理方法探讨[J].中华放射学杂志,2002,36(2):114-117.
19.关守海,单鸿,姜在波,等.经微导管局部灌注无水乙醇治疗肝癌高流量性动静脉瘘[J].中华放射学杂志,2002,36(11):997-200.
20.Furuse J,Iwasaka M,Yoshino M,et al.Hepatocellular carcinoma with portal vein tumor thrombus:embolization of arterioportal shunts[J].Radiology,1997,204(3):787-790.
21.何国治,王建华,刘清欣,等.32例肝癌合并肝内动静脉瘘的介入治疗体会[J].中国临床医学,2000,7(2):214-215.
22.张电波,肖湘生,欧阳强,等.肝癌伴肝动静脉瘘的血供造影表现及其临床意义[J].中国医学影像杂志,2001,9(5):375-376.
23.李槐,曾辉英,杨玲,等.影响中晚期原发性肝癌远期疗效的因素-以肝动脉化疗栓塞为主的多模式治疗[J].中国医学影像技术,2000,16(11):930-933.
24.刘崎,田建明,贾雨辰,等.肝癌并门脉主干癌栓的介入治疗及其预后的影响因素[J].中华放射学杂志,1999,33(8):538-541.
25.刘嵘,王建华,周康荣,等.肝动脉化疗栓塞治疗原发性肝癌中碘油沉积良好患者临床疗效观察(附144例报告)[J].介入放射学杂志,2001,10(4):212-214.
26.程红岩,徐爱民,陈栋,等.肝癌介入治疗的相关因素与死亡时间关系探讨[J].中华肿瘤杂志,2001,23(6):497-499.
27.戚跃勇,邹利光,黄小兵,等.门静脉阻断对肝癌VEGF表达影响的实验研究[J].临床放射学杂志,2007,26(4):395-398.
28.潘杰,杨宁,张中中,等.经门静脉无水酒精选择性肝段硬化术的动物实验研究[J].中华放射学杂志,2003,37(1):25-27.
29.Matsui O,Kadoya M,Yoshikawa J,et al.Small hepatocellular carcinoma:treatment with subsegmental transcatheter arterial embolization[J].Radiology,1993,188(1):79-83.
30.Nishmine K,Uchida H,Matsuo N,et al.Segmental transarterial chemoembolization with lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma:follow-up CT and therapeutic results[J].Cancer chemotherapy and pharmacology,1994,33(Suppl):60-80.
31.王建华,周康荣,颜志平,等.小肝癌的介入治疗研究(附42例报告)[J].中华放射学杂志,2000,34(12):823-826.
32.Sakamoto Ⅰ,Aso N,Nagaoki K,et al.Complications associated with transcatheter arterial embolization for hepatic tumors[J].Radiographics,1998,18(3):605-619.
33.罗鹏飞,符力,陈晓明,等.肝癌介入后胆汁瘤的形成与临床意义[J].中华放射学杂志,2000,34(11):757-760.
34.Chung JW,Park JH,Choi L,et al.Hepatic tumors:predisposing factors for complications of transcatheter oily chemoemboization[J].Radiology,1996,198(1):33-40.
35.梁力建,张继红.肝动脉栓塞术在肝癌治疗中的临床应用及评价[J].中国实用外科杂志,2004,24(8):504-506.
36.Kamada K,Kitamoto M,Aikata H,et al.Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma[J].American Journal of Surgery,2002,184(3):284-290.
1.周泽健,罗鹏飞,邵培坚,等.介入治疗后38例中晚期肝癌患者生存5年以上的因素分析[J].中华放射学杂志,2002,36(9):792-796.
2.刘嵘,王建华,颜志平,等.原发性肝癌综合介入治疗后存活5年以上56例患者临床分析[J].介入放射学杂志,2007,16(3):155-158.
3.中国抗癌协会肝癌专业委员会.原发性肝癌诊断标准[J].中华肝脏病杂志,2000.8(3):135
4.Bruix J,Sherman M.Management of hepatocellular carcinoma[J].Hepatology,2005,42(5):1208-1236.
5.Sherman M.Alphafetoprotein:an obituary[J].Journal of hepatology,2001,34(4):603-605.
6.Koda M,Murawaki Y,Mitsuda A,et al.Combination therapy withtranscatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alonefor patients with small hepatocellular carcinoma:a randomized control study[J].Cancer,2001,92(6):1516-1524.
7.刘铁峰,李湘义,张俊萍,等.微导管系统在原发性肝癌介入治疗中的临床应用[J].实用医学影像杂志,2004,5(4):185-187
8.王建华,周康荣.肝癌综合性介入治疗规范化方案(草案)[J].临床放射学杂志,2002,21(7):497-500.
9.Kim P,Prapong W,Sze DY,et al.Treatment of hepatocellular carcinoma with sub-selective transcatheter arterial oily chemoinfusion[J].Techniques in vascular and interventional radiology,2002,5(3):127-131
10.Risse JH,Menzle C,Grunwald F,et al.Therapy of hepatocellular carcinoma with lodized oil[J].Romanian journal of gastroenterology, 2004,13(2):119-124.
11.Higashihara H,Okaxaki M,Transcatheter arterial chemoembolization of hepatocellular carcinoma:a Japanese experience[J].Hepatogastroenterology,2002,49(43):72-78.
12.曾庆乐,李彦豪,陈勇,等.微导管超选择插管在肝癌介入治疗中的应用[J].中国医学影像技术,2002,18(2):113-115
13.刘嵘,王建华,周康荣,等.微导管在肝动脉化疗栓塞治疗原发性肝癌的临床应用[J].临床放射学杂志,2002,21(3):226-229.
14.邓梨平,于淼,张金山,等.微导管在肝癌介入栓塞治疗中的应用[J].中国医学影像技术,2008,24(4):591-593.
15.吴建兵,李凌,许美珍,等.无水乙醇肝段栓塞联合TACE治疗小肝癌20例[J].实用临床医学,2007,8(9):15-17.
16.刘嵘,王建华,周康荣,等.肝动脉化疗栓塞治疗原发性肝癌中碘油沉积良好患者临床疗效观察(附144例报告)[J].介入放射学杂志,2001,10(4):212-214.
17.Kamada K,Kitamoto M,Aikata H,et al.Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma[J].American Journal of Surgery,2002,184(3):284-290.
18.李欣,冯敢生,郑传胜,等.肝动脉化疗栓塞对肿瘤血管生成影响的实验研究[J].中华放射学杂志,2002,36(8):689-693.
19.吴汉平,冯敢生.肝癌介入治疗的现状与展望[J].临床放射学杂志,2005,24(3):273-276.
20.An FQ,Matsuda M,Fujii H,et al.Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinoma[J].Journal of Cancer Research and Clinical Oncology,2000,126(3):153-160.
21.李震,胡道予,褚倩,等.肝癌化疗栓塞术后肝细胞周期的研究[J].临床放射学杂志,2003,22(4):335-339.
1.Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].CA:A Cancer Journal for Clinicians,2005,55(2):74-108.
2.Momosaki S,Nakashima Y,Kojiro M,et al.HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma[J].Journal of Viral Hepatitis,2005,12(3):325-329.
3.曾运红,谭卫仙.原发性肝癌发病主要危险因素的Meta分析[J].现代预防医学,2004,31(2):172-174.
4.Sturm JW,Keese MA,Bonninghoff RG,et al.Locally ablative therapies of hepatocellular carcinoma[J].Onkologie,2001,24(Suppl 5):35-45.
5.Livraghi T,Goldberg SN,Lazzaroni S,et al.Hepatocellular Carcinoma:Radiofrequcncy Ablation of Medium and Large Lesion[J].Radiology,2000,214(7):761-768.
6.Dong BW,Liang P,Yu XL,et al.Percutaneous Sonographically Guided Microwave Cagulation Therapy for Hepatocellular Carcinoma:Result in 234 Patients[J].Amercian Journal of Roentgenology,2003, 180(15):1547-1555.
7.王建华,颜志平,程洁敏,等.肝癌介入治疗的远期疗效和影响因素分析(附400例报告)[J].中国医学影像技术,1999,15(2):140-142.
8.王建华,周康荣.肝癌综合性介入治疗规范化方案(草案)[J].临床放射学杂志,2002,21(7):497-500.
9.Bruix J,Sherman M.Management of hepatocellular carcinoma[J].Hepatology,2005,42(5):1208-1236.
10.Marrero JA,Lok AS.Newer markers for hepatocellular carcinoma [J].Gastroenterology,2004,127(suppl 1):113-119.
11.Sherman M.Alphafetoprotein:an obituary[J].Journal of hepatology,2001,34(4):603-605.
12.Ishizuka H,Nakayama T,Matsuoka S,et al.Prediction of the development of hepato-cellular-carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-L-fucosidase activity[J].Internal Medicine 1999,38(12):927-931.
13.Kumada T,Nakano S,rakeda I,et al.Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma:special reference to imaging diagnosis[J].Journal of hepatology,1999,30(1):125-130.
14.Capurro M,Wanless IR,Sherman M,et al.Glypican-3:a novel serum and histochemical marker for hepatocellular carcinoma[J].Gastroenterology,2003,125(1):89-97.
15.刘华丽,唐容,杨丽,等.超声、CT对肝癌诊断的对比分析[J].四川医学,2005,26(6):664.
16.Hatanaka K,Kudo M,Minami Y,et al.Differential diagnosis of hepatic tumors:value of contrast-enhanced harmonic sonography using the newly developed contrast agent,Sonazoid.Intervirology,2008,51(Suppl 1):61-69.
17.Lencioni R,Cioni D,Crocetti L,et al.Early-stage hepatocellular carcinoma in patients with cirrhosis:long-term results of percutaneous image-guided radiofrequency ablation[J].Radiology,2005,234(3):961-967.
18.陈卫霞,闵鹏秋,宋彬,等.肝细胞癌螺旋CT同层动态扫描表现与肿瘤血管生成的相关性[J].中华放射学杂志,2001,35:247-252.
19.Semelka RC,Martin DR,Balci C,et al.Focal liver lesions:comparison of dual-phase CT and multisequence multiplanar MR imaging including dynamic gadolinium enhancement[J].Journal of magnetic resonance imaging,2001.13(3):397-401.
20.Shinmura R,Matsui O,Kobayashi S,et al.Cirrhotic nodules:association between MR imaging signal intensity and intranodular blood supply.Radiology,2005,237(2):512-519.
21.杨正汉,周诚,陈敏,等.肝脏发育不良结节癌变的CT、MRI评价[J].中华放射学杂志,2004,38:494-498.
22.中国抗癌协会肝癌专业委员会.原发性肝癌诊断标准[J].中华肝脏病杂志,2000,8(3):135.
23.Van Vlierberghe H,Borbath I,Delwaide J,et al.BASL guidelines for the surveillance,diagnosis and treatment of hepatocellular carcinoma[J].Acta Gastroenterologica Belgica,2004,67(1):14-25
24.Pooh RT,Fan ST.Evaluation of the new AJCC/UICC staging system for hepatocellular carcinoma after hepatic resection in Chinese patients [J].Surgical oncology clinics of North America,2003,12(1):35-50.
25.Sala M,Forner A,Varela M,et al.Prognostic prediction in patients with hepatocellular carcinoma[J].Seminars in liver disease,2005,25(2):171-180.
26.Beaugrand M,N' Kontchou G,Seror O,et al.Local/regional and systemic treatments of hepatocellular carcinoma[J].Seminars in liver disease,2005,25(2):201-211.
27.Shiina S,Teratani T,Obi S,et al.A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma[J].Gastroenterology.2005,129(1):122-130.
28.Livraghi T,So]biati L,Meloni MF,et al.Treatment of focal liver tumors with percutaneous radio-frequency ablation:complications encountered in a multicenter study[J].Radiology,2003,226(2):441-451.
29.Shibata T,Iimuro Y,Yamamoto Y,et al.Small hepatocellular carcinoma:comparison of radio-frequency ablation and percutaneous microwave coagulation therapy[J].Radiology.2002,223(2):331-337.
30.王建华.肝癌综合介入治疗的现状[J].中华肝脏病杂志,2005,13(10):721-723.
31.陆才德.肝脏肿瘤的血供[J].国外医学:肿瘤学分册,1991,1(1):19-21.
32.罗建钧,颜志平,王建华,等.微球+碘化油联合栓塞与碘化油单独栓塞治疗肝癌的比较研究[J].中国医学计算机成像杂志,2008,14(2):154-159.
33.Matsuo N,Uchida H,Sakaguchi H,et al.Optimal lipiodol volume in transcatheter arterial chemoembolotherapy for hepatocellular carcinoma:study based on lipiodol accumulation patterns and histopathologic findings[J].Seminars in Oncology,1997,24(2 Suppl 6):61-70.
34.曾庆乐,李彦豪,陈勇,等.微导管超选择插管在肝癌介入治疗中的应用[J].中国医学影像技术,2002,18(2):113-115
35.高伟明,孙东立,袁明远.碘化油用量与原发性肝癌介入治疗疗效关系研究[J].现代诊断与治疗,2006,17(6):346-347.
36.王建华.肝癌的介入治疗[J].实用医学杂志,2001,17(4):278-280.
37.Lu W,Li Y,He X,et al.Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis:evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors[J].Hepatogastroenterology,2003,50(54):2079-2083.
38.王建华,颜志平,王小林,等.肝癌介入治疗若干问题探讨[J].中国肿瘤,1997,6(1):3-6.
39.Matsui O,Kadoya M,Yoshikawa J,et al.Small hepatocellular carcinoma:treatment with subsegmental transcatheter arterial embolization[J].Radiology,1993,188(1):79-83.
40.Nishmine K,Uchida H,Matsuo N,et al.Segmental transarterial chemoembolization with lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma:follow-up CT and therapeutic results[J].Cancer Chemotherapy and Pharmacology,1994,33(Suppl):60-80.
41.王建华,周康荣,颜志平,等.小肝癌的介入治疗研究(附42例报告)[J].中华放射学杂志,2000,34(12):823-826.
42.Llovet JM,Bruix J.Systematic review of randomized trials for unresectable hepatocellular carcinoma:Chemoembolization improves survival[J].Hepatology.2003 37(2):429-442.
43.Bisuth H,Moron M,Sherlock D,et al.Primart treatment of hepatocellular carcinoma by arterial chemoembolization[J].American journal of surgery,1992,163(4):387-394.
44.曾昭冲.原发性肝癌放射治疗的争论与共识[J].临床肿瘤学杂志,2008,13(2):97-104.
45.姚问我,颜志平,王建华,等.介入治疗肝癌伴门脉癌栓的若干问题[J].中国临床医学,2007,14(6):810-811.
46.龚高全,王小林,周康荣,等.肝癌伴门静脉癌栓的金属内支架治疗的初步研究[J].临床放射学杂志 2003,22(6):498-500.
47.王小林,陈颐,王建华,等.肝门部肝癌合并梗阻性黄疸的介入治疗[J].中国医学计算机成像杂志,2005,11(6):412-415.
48.刘清欣,王建华,罗剑钧,等.肝癌致下腔静脉梗阻的内支架治疗[J].介入放射学杂志,2007,16(3):168-170.
49.程洁敏,王建华,颜志平,等.肺动脉化疗药盒埋置术治疗肝癌肺转移[J].介入放射学杂志,2000,9(3):158-160.
2.Momosaki S,Nakashima Y,Kojiro M,et al.HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma.Journal of Viral Hepatitis,2005,12(3):325-329.
3.葛祖恂,黄介飞,陆守曾,等.国内丙型肝炎病毒感染与肝细胞癌关系的19个病例对照研究的Meta分析[J].中国卫生统计,1997,14(1):10-12.
4.Llovet JM,Burroughs A,Bruix J.Hepatocellular carcinoma[J].The Lancet,2003,362(9399):1907-1917.
5.曾运红,谭卫仙.原发性肝癌发病主要危险因素的Meta分析[J].现代预防医学,2004,3l(2):172-174.
6.曹海霞,丁建华,吴建中,等.饮酒习惯、HBsAg与原发性肝癌关系[J].中国肿瘤,2004,13(5):280-282.
7.Solbiati L,Coldberg SN,Lerace T,et al.Hepatic Metastases:Percutarleous radiofrequency ablation with cooledtip electrodes[J].Radiology,1997,205(2):367-373.
8.褚光平,蔡敬铭,刘强,等.青年人原发性肝癌的治疗与预后分析[J].中国肿瘤临床,2005,32(22):1299-1301.
9.Sturm JW,Keese MA,Bonninghoff RG,et al.Locally ablative therapies of hepatocellular carcinoma[J].Onkologie,2001,24(Suppl 5):35-45.
10.王建华.呼唤规范化的肝癌介入治疗[J].介入放射学杂志,2007,16(3):145-147.
11.Higuchi T,Kikuchi M,Okuzaki.Hepatocellular Carcinoma after Transcatheter Hepatic Arterial Embolization:a Histopathologic Study of 84 Resected Cases[J].Cancer,1994,73(31):2259-2261.
12.吴孟超.原发性肝癌的诊断及治疗进展[J].华夏医药,2006,4(1):10-11.
13.Livraghi T,Goldberg SN,Lazzaroni S,et al.Hepatocellular Carcinoma:Radiofrequcncy Ablation of Medium and Large Lesion[J].Radiology,2000,214(7):761-768.
14.Dong BW,Liang P,Yu XL,et al.Percutaneous Sonographically Guided Microwave Cagulation Therapy for Hepatocel]ular Carcinoma:Result in 234 Patients[J].Amercian Journal of Roentgenology,2003, 180(15):1547-1555.
15.Koda M,Murawaki Y,Mitsuda A,et al.Combination therapy withtranscatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alonefor patients with small hepatocellular carcinoma:a randomized control study[J].Cancer,2001,92(6):1516-1524.
16.王建华,周康荣.肝癌综合性介入治疗规范化方案(草案)[J].临床放射学杂志,2002,21:497-500.
1.中国抗癌协会肝癌专业委员会.原发性肝癌诊断标准[J].中华肝脏病杂志,2000,8(3):135.
2.王建华.肝癌综合介入治疗的现状[J].中华肝脏病杂志,2005,13(10):721-723.
3.陆才德.肝脏肿瘤的血供[J].国外医学:肿瘤学分册,1991,1(1):19-21.
4.Ackeman NB.Experimental Studies on the Role of the Portal Circulation in Hepatic Tumor Vascularity[J].Cancer,1986,58(8):1653-1657.
5.Doppman JL,Girton M,Kahn ER.Proximal versus peripheral hepatic artery embolization experimental study in monkeys[J].Radiology,1978,128(1):577-588.
6.罗建钧,颜志平,王建华,等.微球+碘化油联合栓塞与碘化油单独栓塞治疗肝癌的比较研究[J].中国医学计算机成像杂志,2008,14(2):154-159.
7.Matsuo N,Uchida H,Sakaguchi H,et al.Optimal lipiodol volume in transcatheter arterial chemoembolotherapy for hepatocellular carcinoma:study based on lipiodol accumulation patterns and histopathologic findings[J].Seminars in Oncology,1997,24(2 Suppl 6):61-70.
8.陈晓明,罗鹏飞,邵培坚,等.肝癌节段性栓塞化疗与常规栓塞化疗的比较研究[J].中华放射学杂志,2000,34(4):271-273.
9.曾庆乐,李彦豪,陈勇,等.微导管超选择插管在肝癌介入治疗中的应用[J].中国医学影像技术,2002,18(2):113-115
10.周泽健,罗鹏飞,邵培坚,等.介入治疗后38例中晚期肝癌患者生存5年以上的因素分析[J].中华放射学杂志,2002,36(9):792-796.
11.高伟明,孙东立,袁明远.碘化油用量与原发性肝癌介入治疗疗效关系研究[J].现代诊断与治疗,2006,17(6):346-347.
12.王建华.肝癌的介入治疗[J].实用医学杂志,200l,17(4):278-280.
13.刘嵘,王建华,颜志平,等.原发性肝癌综合介入治疗后存活5年以上56例患者临床分析[J].介入放射学杂志,2007,16(3):155-158.
14.肖承江,郑丽吟,蒋晓红.肝动脉栓塞化疗对肝损害的观察(附100例分析)[J].中华放射学杂志,1997,31(11):777-779.
15.姚问我,颜志平,王建华,等.介入治疗肝癌伴门脉癌栓的若干问题[J].中国临床医学,2007,14(6):810-811.
16.朱林忠,杨仁杰.原发性肝癌合并动静脉瘘的数字减影血管造影表现及介入治疗[J].北京大学学报(医学版),2008,40(2):129-134.
17.谭文华.原发性肝癌合并肝动静脉瘘的栓塞治疗(附10例报告)[J].广西医科大学学报,2003,20(4):600.
18.罗鹏飞,陈晓明,张良明,等.肝癌合并动静脉瘘的处理方法探讨[J].中华放射学杂志,2002,36(2):114-117.
19.关守海,单鸿,姜在波,等.经微导管局部灌注无水乙醇治疗肝癌高流量性动静脉瘘[J].中华放射学杂志,2002,36(11):997-200.
20.Furuse J,Iwasaka M,Yoshino M,et al.Hepatocellular carcinoma with portal vein tumor thrombus:embolization of arterioportal shunts[J].Radiology,1997,204(3):787-790.
21.何国治,王建华,刘清欣,等.32例肝癌合并肝内动静脉瘘的介入治疗体会[J].中国临床医学,2000,7(2):214-215.
22.张电波,肖湘生,欧阳强,等.肝癌伴肝动静脉瘘的血供造影表现及其临床意义[J].中国医学影像杂志,2001,9(5):375-376.
23.李槐,曾辉英,杨玲,等.影响中晚期原发性肝癌远期疗效的因素-以肝动脉化疗栓塞为主的多模式治疗[J].中国医学影像技术,2000,16(11):930-933.
24.刘崎,田建明,贾雨辰,等.肝癌并门脉主干癌栓的介入治疗及其预后的影响因素[J].中华放射学杂志,1999,33(8):538-541.
25.刘嵘,王建华,周康荣,等.肝动脉化疗栓塞治疗原发性肝癌中碘油沉积良好患者临床疗效观察(附144例报告)[J].介入放射学杂志,2001,10(4):212-214.
26.程红岩,徐爱民,陈栋,等.肝癌介入治疗的相关因素与死亡时间关系探讨[J].中华肿瘤杂志,2001,23(6):497-499.
27.戚跃勇,邹利光,黄小兵,等.门静脉阻断对肝癌VEGF表达影响的实验研究[J].临床放射学杂志,2007,26(4):395-398.
28.潘杰,杨宁,张中中,等.经门静脉无水酒精选择性肝段硬化术的动物实验研究[J].中华放射学杂志,2003,37(1):25-27.
29.Matsui O,Kadoya M,Yoshikawa J,et al.Small hepatocellular carcinoma:treatment with subsegmental transcatheter arterial embolization[J].Radiology,1993,188(1):79-83.
30.Nishmine K,Uchida H,Matsuo N,et al.Segmental transarterial chemoembolization with lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma:follow-up CT and therapeutic results[J].Cancer chemotherapy and pharmacology,1994,33(Suppl):60-80.
31.王建华,周康荣,颜志平,等.小肝癌的介入治疗研究(附42例报告)[J].中华放射学杂志,2000,34(12):823-826.
32.Sakamoto Ⅰ,Aso N,Nagaoki K,et al.Complications associated with transcatheter arterial embolization for hepatic tumors[J].Radiographics,1998,18(3):605-619.
33.罗鹏飞,符力,陈晓明,等.肝癌介入后胆汁瘤的形成与临床意义[J].中华放射学杂志,2000,34(11):757-760.
34.Chung JW,Park JH,Choi L,et al.Hepatic tumors:predisposing factors for complications of transcatheter oily chemoemboization[J].Radiology,1996,198(1):33-40.
35.梁力建,张继红.肝动脉栓塞术在肝癌治疗中的临床应用及评价[J].中国实用外科杂志,2004,24(8):504-506.
36.Kamada K,Kitamoto M,Aikata H,et al.Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma[J].American Journal of Surgery,2002,184(3):284-290.
1.周泽健,罗鹏飞,邵培坚,等.介入治疗后38例中晚期肝癌患者生存5年以上的因素分析[J].中华放射学杂志,2002,36(9):792-796.
2.刘嵘,王建华,颜志平,等.原发性肝癌综合介入治疗后存活5年以上56例患者临床分析[J].介入放射学杂志,2007,16(3):155-158.
3.中国抗癌协会肝癌专业委员会.原发性肝癌诊断标准[J].中华肝脏病杂志,2000.8(3):135
4.Bruix J,Sherman M.Management of hepatocellular carcinoma[J].Hepatology,2005,42(5):1208-1236.
5.Sherman M.Alphafetoprotein:an obituary[J].Journal of hepatology,2001,34(4):603-605.
6.Koda M,Murawaki Y,Mitsuda A,et al.Combination therapy withtranscatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alonefor patients with small hepatocellular carcinoma:a randomized control study[J].Cancer,2001,92(6):1516-1524.
7.刘铁峰,李湘义,张俊萍,等.微导管系统在原发性肝癌介入治疗中的临床应用[J].实用医学影像杂志,2004,5(4):185-187
8.王建华,周康荣.肝癌综合性介入治疗规范化方案(草案)[J].临床放射学杂志,2002,21(7):497-500.
9.Kim P,Prapong W,Sze DY,et al.Treatment of hepatocellular carcinoma with sub-selective transcatheter arterial oily chemoinfusion[J].Techniques in vascular and interventional radiology,2002,5(3):127-131
10.Risse JH,Menzle C,Grunwald F,et al.Therapy of hepatocellular carcinoma with lodized oil[J].Romanian journal of gastroenterology, 2004,13(2):119-124.
11.Higashihara H,Okaxaki M,Transcatheter arterial chemoembolization of hepatocellular carcinoma:a Japanese experience[J].Hepatogastroenterology,2002,49(43):72-78.
12.曾庆乐,李彦豪,陈勇,等.微导管超选择插管在肝癌介入治疗中的应用[J].中国医学影像技术,2002,18(2):113-115
13.刘嵘,王建华,周康荣,等.微导管在肝动脉化疗栓塞治疗原发性肝癌的临床应用[J].临床放射学杂志,2002,21(3):226-229.
14.邓梨平,于淼,张金山,等.微导管在肝癌介入栓塞治疗中的应用[J].中国医学影像技术,2008,24(4):591-593.
15.吴建兵,李凌,许美珍,等.无水乙醇肝段栓塞联合TACE治疗小肝癌20例[J].实用临床医学,2007,8(9):15-17.
16.刘嵘,王建华,周康荣,等.肝动脉化疗栓塞治疗原发性肝癌中碘油沉积良好患者临床疗效观察(附144例报告)[J].介入放射学杂志,2001,10(4):212-214.
17.Kamada K,Kitamoto M,Aikata H,et al.Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma[J].American Journal of Surgery,2002,184(3):284-290.
18.李欣,冯敢生,郑传胜,等.肝动脉化疗栓塞对肿瘤血管生成影响的实验研究[J].中华放射学杂志,2002,36(8):689-693.
19.吴汉平,冯敢生.肝癌介入治疗的现状与展望[J].临床放射学杂志,2005,24(3):273-276.
20.An FQ,Matsuda M,Fujii H,et al.Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinoma[J].Journal of Cancer Research and Clinical Oncology,2000,126(3):153-160.
21.李震,胡道予,褚倩,等.肝癌化疗栓塞术后肝细胞周期的研究[J].临床放射学杂志,2003,22(4):335-339.
1.Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].CA:A Cancer Journal for Clinicians,2005,55(2):74-108.
2.Momosaki S,Nakashima Y,Kojiro M,et al.HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma[J].Journal of Viral Hepatitis,2005,12(3):325-329.
3.曾运红,谭卫仙.原发性肝癌发病主要危险因素的Meta分析[J].现代预防医学,2004,31(2):172-174.
4.Sturm JW,Keese MA,Bonninghoff RG,et al.Locally ablative therapies of hepatocellular carcinoma[J].Onkologie,2001,24(Suppl 5):35-45.
5.Livraghi T,Goldberg SN,Lazzaroni S,et al.Hepatocellular Carcinoma:Radiofrequcncy Ablation of Medium and Large Lesion[J].Radiology,2000,214(7):761-768.
6.Dong BW,Liang P,Yu XL,et al.Percutaneous Sonographically Guided Microwave Cagulation Therapy for Hepatocellular Carcinoma:Result in 234 Patients[J].Amercian Journal of Roentgenology,2003, 180(15):1547-1555.
7.王建华,颜志平,程洁敏,等.肝癌介入治疗的远期疗效和影响因素分析(附400例报告)[J].中国医学影像技术,1999,15(2):140-142.
8.王建华,周康荣.肝癌综合性介入治疗规范化方案(草案)[J].临床放射学杂志,2002,21(7):497-500.
9.Bruix J,Sherman M.Management of hepatocellular carcinoma[J].Hepatology,2005,42(5):1208-1236.
10.Marrero JA,Lok AS.Newer markers for hepatocellular carcinoma [J].Gastroenterology,2004,127(suppl 1):113-119.
11.Sherman M.Alphafetoprotein:an obituary[J].Journal of hepatology,2001,34(4):603-605.
12.Ishizuka H,Nakayama T,Matsuoka S,et al.Prediction of the development of hepato-cellular-carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-L-fucosidase activity[J].Internal Medicine 1999,38(12):927-931.
13.Kumada T,Nakano S,rakeda I,et al.Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma:special reference to imaging diagnosis[J].Journal of hepatology,1999,30(1):125-130.
14.Capurro M,Wanless IR,Sherman M,et al.Glypican-3:a novel serum and histochemical marker for hepatocellular carcinoma[J].Gastroenterology,2003,125(1):89-97.
15.刘华丽,唐容,杨丽,等.超声、CT对肝癌诊断的对比分析[J].四川医学,2005,26(6):664.
16.Hatanaka K,Kudo M,Minami Y,et al.Differential diagnosis of hepatic tumors:value of contrast-enhanced harmonic sonography using the newly developed contrast agent,Sonazoid.Intervirology,2008,51(Suppl 1):61-69.
17.Lencioni R,Cioni D,Crocetti L,et al.Early-stage hepatocellular carcinoma in patients with cirrhosis:long-term results of percutaneous image-guided radiofrequency ablation[J].Radiology,2005,234(3):961-967.
18.陈卫霞,闵鹏秋,宋彬,等.肝细胞癌螺旋CT同层动态扫描表现与肿瘤血管生成的相关性[J].中华放射学杂志,2001,35:247-252.
19.Semelka RC,Martin DR,Balci C,et al.Focal liver lesions:comparison of dual-phase CT and multisequence multiplanar MR imaging including dynamic gadolinium enhancement[J].Journal of magnetic resonance imaging,2001.13(3):397-401.
20.Shinmura R,Matsui O,Kobayashi S,et al.Cirrhotic nodules:association between MR imaging signal intensity and intranodular blood supply.Radiology,2005,237(2):512-519.
21.杨正汉,周诚,陈敏,等.肝脏发育不良结节癌变的CT、MRI评价[J].中华放射学杂志,2004,38:494-498.
22.中国抗癌协会肝癌专业委员会.原发性肝癌诊断标准[J].中华肝脏病杂志,2000,8(3):135.
23.Van Vlierberghe H,Borbath I,Delwaide J,et al.BASL guidelines for the surveillance,diagnosis and treatment of hepatocellular carcinoma[J].Acta Gastroenterologica Belgica,2004,67(1):14-25
24.Pooh RT,Fan ST.Evaluation of the new AJCC/UICC staging system for hepatocellular carcinoma after hepatic resection in Chinese patients [J].Surgical oncology clinics of North America,2003,12(1):35-50.
25.Sala M,Forner A,Varela M,et al.Prognostic prediction in patients with hepatocellular carcinoma[J].Seminars in liver disease,2005,25(2):171-180.
26.Beaugrand M,N' Kontchou G,Seror O,et al.Local/regional and systemic treatments of hepatocellular carcinoma[J].Seminars in liver disease,2005,25(2):201-211.
27.Shiina S,Teratani T,Obi S,et al.A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma[J].Gastroenterology.2005,129(1):122-130.
28.Livraghi T,So]biati L,Meloni MF,et al.Treatment of focal liver tumors with percutaneous radio-frequency ablation:complications encountered in a multicenter study[J].Radiology,2003,226(2):441-451.
29.Shibata T,Iimuro Y,Yamamoto Y,et al.Small hepatocellular carcinoma:comparison of radio-frequency ablation and percutaneous microwave coagulation therapy[J].Radiology.2002,223(2):331-337.
30.王建华.肝癌综合介入治疗的现状[J].中华肝脏病杂志,2005,13(10):721-723.
31.陆才德.肝脏肿瘤的血供[J].国外医学:肿瘤学分册,1991,1(1):19-21.
32.罗建钧,颜志平,王建华,等.微球+碘化油联合栓塞与碘化油单独栓塞治疗肝癌的比较研究[J].中国医学计算机成像杂志,2008,14(2):154-159.
33.Matsuo N,Uchida H,Sakaguchi H,et al.Optimal lipiodol volume in transcatheter arterial chemoembolotherapy for hepatocellular carcinoma:study based on lipiodol accumulation patterns and histopathologic findings[J].Seminars in Oncology,1997,24(2 Suppl 6):61-70.
34.曾庆乐,李彦豪,陈勇,等.微导管超选择插管在肝癌介入治疗中的应用[J].中国医学影像技术,2002,18(2):113-115
35.高伟明,孙东立,袁明远.碘化油用量与原发性肝癌介入治疗疗效关系研究[J].现代诊断与治疗,2006,17(6):346-347.
36.王建华.肝癌的介入治疗[J].实用医学杂志,2001,17(4):278-280.
37.Lu W,Li Y,He X,et al.Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis:evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors[J].Hepatogastroenterology,2003,50(54):2079-2083.
38.王建华,颜志平,王小林,等.肝癌介入治疗若干问题探讨[J].中国肿瘤,1997,6(1):3-6.
39.Matsui O,Kadoya M,Yoshikawa J,et al.Small hepatocellular carcinoma:treatment with subsegmental transcatheter arterial embolization[J].Radiology,1993,188(1):79-83.
40.Nishmine K,Uchida H,Matsuo N,et al.Segmental transarterial chemoembolization with lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma:follow-up CT and therapeutic results[J].Cancer Chemotherapy and Pharmacology,1994,33(Suppl):60-80.
41.王建华,周康荣,颜志平,等.小肝癌的介入治疗研究(附42例报告)[J].中华放射学杂志,2000,34(12):823-826.
42.Llovet JM,Bruix J.Systematic review of randomized trials for unresectable hepatocellular carcinoma:Chemoembolization improves survival[J].Hepatology.2003 37(2):429-442.
43.Bisuth H,Moron M,Sherlock D,et al.Primart treatment of hepatocellular carcinoma by arterial chemoembolization[J].American journal of surgery,1992,163(4):387-394.
44.曾昭冲.原发性肝癌放射治疗的争论与共识[J].临床肿瘤学杂志,2008,13(2):97-104.
45.姚问我,颜志平,王建华,等.介入治疗肝癌伴门脉癌栓的若干问题[J].中国临床医学,2007,14(6):810-811.
46.龚高全,王小林,周康荣,等.肝癌伴门静脉癌栓的金属内支架治疗的初步研究[J].临床放射学杂志 2003,22(6):498-500.
47.王小林,陈颐,王建华,等.肝门部肝癌合并梗阻性黄疸的介入治疗[J].中国医学计算机成像杂志,2005,11(6):412-415.
48.刘清欣,王建华,罗剑钧,等.肝癌致下腔静脉梗阻的内支架治疗[J].介入放射学杂志,2007,16(3):168-170.
49.程洁敏,王建华,颜志平,等.肺动脉化疗药盒埋置术治疗肝癌肺转移[J].介入放射学杂志,2000,9(3):158-160.